Sight Sciences, Inc. (SGHT)
| Market Cap | 235.47M |
| Revenue (ttm) | 77.36M |
| Net Income (ttm) | -38.43M |
| Shares Out | 54.01M |
| EPS (ttm) | -0.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 126,859 |
| Open | 4.300 |
| Previous Close | 4.320 |
| Day's Range | 4.300 - 4.430 |
| 52-Week Range | 2.740 - 9.236 |
| Beta | 2.49 |
| Analysts | Buy |
| Price Target | 9.08 (+108.26%) |
| Earnings Date | May 6, 2026 |
About SGHT
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and O... [Read more]
Financial Performance
In 2025, Sight Sciences's revenue was $77.36 million, a decrease of -3.13% compared to the previous year's $79.87 million. Losses were -$38.43 million, -25.40% less than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for SGHT stock is "Buy." The 12-month stock price target is $9.08, which is an increase of 108.26% from the latest price.
News
Sight Sciences Announces the Release of its Sustainability Report
The Sustainability Report provides data for 2023 through 2025 on the Company's environmental, social, and governance initiatives The Sustainability Report provides data for 2023 through 2025 on the Co...
Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
MENLO PARK, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing inno...
Sight Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference
The conference highlighted strong momentum for interventional glaucoma and dry eye, with growing adoption driven by early adopters, reimbursement expansion, and cross-segment synergies. Product innovation and manufacturing diversification support long-term growth, while prudent financial guidance and disciplined investment underpin the outlook.
Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, in...
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing ...
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
Court preserves jury's finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 Court preserves jury's f...
Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Sight Sciences, Inc. (NASDAQ: SGHT). The investigation focuses on Sight S...
Sight Sciences Earnings Call Transcript: Q4 2025
Q4 2025 saw 7% revenue growth, strong gross margins, and reduced operating expenses, with both interventional glaucoma and dry eye segments contributing. 2026 guidance projects 6–14% revenue growth, driven by commercial investments and expanding reimbursement.
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance
MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing ...
Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...
Sight Sciences Transcript: Stifel 2025 Healthcare Conference
Significant progress was made with TearCare's reimbursement and commercialization, supported by strong clinical and economic data. The surgical glaucoma segment gained market share, and disciplined financial management positions the business for growth in both core areas.
Sight Sciences Earnings Call Transcript: Q3 2025
Q3 revenue reached $19.9M, led by surgical glaucoma growth, while dry eye revenue declined as focus shifted to reimbursed market access. Full-year 2025 revenue guidance was raised to $76M–$78M, and operating expenses were reduced. Medicare fee schedules for TearCare and new executive appointments position both segments for growth in 2026.
Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...
Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer
New leadership appointments strengthen Sight Sciences' commitment to advancing our interventional dry eye initiatives and driving scalable operations and growth New leadership appointments strengthen ...
Sight Sciences to Present at Two Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...
Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025
MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...
Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure
MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing inno...
Sight Sciences Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Glaucoma and dry eye markets are evolving toward more interventional, less invasive treatments, with strong clinical evidence and innovation driving adoption. Despite reimbursement headwinds, growth is expected to resume, and payer feedback on new dry eye procedures is positive, targeting policy wins in 2025.
Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments
UnitedHealthcare's Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary UnitedHealthcare's Coverage Pol...
Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO
This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data This report provides an evidenc...
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innova...
Sight Sciences Earnings Call Transcript: Q2 2025
Second quarter revenue reached $19.6 million, driven by strong surgical glaucoma performance and positive OMNI Edge adoption, despite year-over-year declines due to Medicare LCD headwinds. Full year 2025 revenue guidance was raised, and robust clinical data supports ongoing efforts for TearCare reimbursement.
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innov...